Designation of Defactinib as an Orphan drug - Plunkett Consulting Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, is the principal statute governing the regulation of therapeutic goods in Australia. This legislation aims to ensure that therapeutic goods, such as medicines, medical devices, and blood products, are safe, of acceptable quality, and that their benefits outweigh their risks. The Act was introduced to address the need for a comprehensive regulatory framework to protect public health by overseeing the supply, evaluation, and monitoring of therapeutic goods. One of the key policy objectives of the Act is to facilitate access to innovative and orphan drugs, which are medicines developed for the diagnosis, prevention, or treatment of rare diseases or conditions. The Therapeutic Goods Administration (TGA), as the executive arm of the Act, plays a critical role in regulating these therapeutic goods, including the designation of orphan drugs such as Defactinib for rare conditions like malignant mesothelioma. This specific designation, as evidenced by the 2014 Gazette, underscores the Act's intent to support the development and availability of treatments for conditions that affect a small patient population.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration under the Commonwealth of Australia's Department of Health, outlines the regulatory framework governing therapeutic goods. This includes the designation of orphan drugs, which are medications intended to treat rare diseases or conditions. In this context, Defactinib has been designated as an orphan drug for the treatment of malignant mesothelioma. The designation applies to the sponsor of Defactinib, in this instance, Plunkett Consulting Pty Ltd, and pertains to the specific dose form of the drug, which is a tablet. The decision to designate Defactinib as an orphan drug was made by Dr. Anthony Gill, a Delegate of the Secretary, exercising powers under the Therapeutic Goods Regulations 1990. This designation is geographically applicable across the Commonwealth of Australia and is intended to support the development and availability of treatments for rare diseases. The Act does not specify any exclusions or exemptions in this instance, and its application is extended through the subordinate instruments of the Therapeutic Goods Regulations 1990.

Key Provisions

Under the Therapeutic Goods Act 1989, the Therapeutic Goods Administration (TGA) has the authority to designate certain therapeutic goods as orphan drugs (section 41-2). This particular legislation designates Defactinib as an orphan drug for the treatment of malignant mesothelioma (section 16J of the Therapeutic Goods Regulations 1990). This designation recognises that Defactinib is intended for a small patient population with a rare condition, and it facilitates the development and availability of such therapeutic goods. The obligations and requirements imposed by this designation on the parties involved include those outlined in the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990. For instance, the sponsor of Defactinib, which in this case is Plunkett Consulting Pty Ltd, must ensure that the drug meets the required safety, quality, and efficacy standards (section 10 of the Therapeutic Goods Act 1989). The sponsor must also submit relevant documentation and data to the TGA to support the orphan drug designation and any future marketing authorisation applications (section 41-3 of the Therapeutic Goods Act 1989). Breach of the provisions in the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can result in significant legal consequences. For example, section 33DA of the Therapeutic Goods Act 1989 imposes civil penalties for offences related to therapeutic goods, including unauthorised therapeutic goods. The maximum penalty for such offences is AUD 2.2 million for a corporation and AUD 440,000 for an individual, or both imprisonment for up to five years and/or a fine not exceeding AUD 110,000. Additionally, section 33DC of the Therapeutic Goods Act 1989 imposes criminal penalties for serious and repeated offences related to therapeutic goods, with maximum penalties of up to ten years imprisonment and/or fines not exceeding AUD 5.5 million for a corporation and AUD 1.1 million for an individual. These penalties underscore the importance of compliance with the legislative framework governing the designation and marketing of therapeutic goods in Australia.